Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Gastroenterology. 2010 Oct;139(4):1115-27. doi: 10.1053/j.gastro.2010.08.023. Epub 2010 Aug 19.
Proton pump (H(+)/K(+)-adenosine triphosphatase) inhibitors (PPIs) are widely used to treat patients with acid-related disorders because they are generally perceived to be safe and effective. However, as with any pharmacologic agent, they have the potential for side effects. Many studies have examined the side effects of long-term or short-term PPI exposure. We review the mechanism of action of PPIs, focusing on recently released products that might have greater risks of adverse effects than older products because of increased potency and/or duration of action. We summarize the data available on the putative adverse effects of PPI therapy and propose guidelines for clinicians who prescribe these agents to limit the potential for adverse outcomes in users of these effective therapeutic agents.
质子泵抑制剂（H(+)/K(+)-三磷酸腺苷酶）被广泛用于治疗酸相关疾病的患者，因为它们通常被认为是安全有效的。然而，就像任何药物一样，它们也有产生副作用的可能性。许多研究已经研究了长期或短期质子泵抑制剂暴露的副作用。我们回顾了质子泵抑制剂的作用机制，重点关注最近发布的产品，由于效力和/或作用持续时间的增加，这些产品可能比旧产品有更大的不良反应风险。我们总结了质子泵抑制剂治疗可能产生的不良反应的现有数据，并为开具这些药物的临床医生提出了建议，以限制这些有效治疗药物使用者的潜在不良后果。
